Compare · MRK vs REGN
MRK vs REGN
Side-by-side comparison of Merck & Company Inc. (MRK) and Regeneron Pharmaceuticals Inc. (REGN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MRK and REGN operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- MRK is the larger of the two at $365.09B, about 4.5x REGN ($81.95B).
- Over the past year, MRK is up 91.7% and REGN is up 41.8% - MRK leads by 50.0 points.
- MRK has been more active in the news (11 items in the past 4 weeks vs 3 for REGN).
- Both have 25 recent analyst ratings on file.
- Company
- Merck & Company Inc.
- Regeneron Pharmaceuticals Inc.
- Price
- $148.77+0.50%
- $787.54-1.04%
- Market cap
- $365.09B
- $81.95B
- 1M return
- -2.82%
- -3.36%
- 1Y return
- +91.74%
- +41.78%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 1991
- News (4w)
- 11
- 3
- Recent ratings
- 25
- 25
Merck & Company Inc.
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health segments. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as vaccine products. The Animal Health segment provides discovers, develops, manufactures, and markets a range of veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as a suite of digitally connected identification, traceability, and monitoring products. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; and Ridgeback Biotherapeutics. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaboration agreement with Gilead Sciences, Inc. to co-develop and co-commercialize long-acting investigational treatment combinations of Lenacapavir and Islatravir in HIV; Amathus Therapeutics to develop treatments for neurodegenerative diseases; and Linnaeus Therapeutics, Inc. to evaluate LNS8801 in combination with KEYTRUDA for patients with advanced cancer. It also has a collaboration with Biomed X Gmbh for building on ongoing research projects in the fields of oncology (DNA damage response and RNA splicing) and autoimmunity (intestinal epithelial barrier in autoimmune diseases); and a collaboration agreement with NGM Biopharmaceuticals, Inc. to focus primarily on the development of novel medicines for unmet patient needs in retinal and CVM diseases, including heart failure. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis in adults, and asthma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; and Kevzara solution for subcutaneous injection for treating rheumatoid arthritis in adults. In addition, the company offers Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer. Further, it offers Inmazeb injection for infection caused by Zaire ebolavirus; and develops product candidates for treating patients with eye, allergic and inflammatory, cancer, cardiovascular and metabolic, pain, infectious, and other diseases. The company has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services. It has collaborations with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York.
Latest MRK
- Ifinatamab Deruxtecan Biologics License Application for Certain Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer Voluntarily Withdrawn
- Merck’s Remigromig, a Tri-specific Agonist of the Wingless-related Integration Site (Wnt) Pathway, Met Primary Endpoint in the Pivotal Phase 2b/3 BRUNELLO Study of Adults with Diabetic Macular Edema
- U.S. FDA Approves Update to the Label for WINREVAIR™ (sotatercept-csrk) to Include Data from the Phase 3 HYPERION Trial Evaluating Adults Recently Diagnosed with Pulmonary Arterial Hypertension (PAH, WHO* Group 1 Pulmonary Hypertension)
- Merck Canada Partners with the Montreal Museum of Fine Arts to Present the North American Premiere of Chiharu Shiota: The Soul Trembles
- Merck’s KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) Approved in Japan for Subcutaneous Administration for All KEYTRUDA® (pembrolizumab) Indications Approved in Japan
- Merck Launches Your Hive of Whole Health to Support Whole Person Care for People Living With HIV
- Perspective Therapeutics Announces Clinical Collaboration and Supply Agreement with Merck to Evaluate [212Pb]PSV359 in Combination with Keytruda® (Pembrolizumab) in FAP-α Positive Solid Tumors
- Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market
- Merck to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
- Merck to Participate in the Wells Fargo 21st Annual Healthcare Conference
Latest REGN
- Regeneron to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on October 30, 2026
- EVP Commercial Mccourt Marion sold $2,002,458 worth of shares (2,346 units at $853.56) as part of a pre-agreed trading plan, decreasing direct ownership by 16% to 12,003 units (SEC Form 4)
- Director Guarini Kathryn exercised 400 shares at a strike of $719.37 and sold $340,000 worth of shares (400 units at $850.00) as part of a pre-agreed trading plan (SEC Form 4)
- FDA Approval for PASATRU issued to REGENERON PHARMACEUTICALS, INC
- EVP General Counsel and Secret Larosa Joseph J exercised 12,282 shares at a strike of $381.92 and covered exercise/tax liability with 9,019 shares, increasing direct ownership by 10% to 36,373 units (SEC Form 4)
- SEC Form N-PX filed by Regeneron Pharmaceuticals Inc.
- EVP Finance CFO Fenimore Christopher R. exercised 6,283 shares at a strike of $381.92 and covered exercise/tax liability with 4,599 shares, increasing direct ownership by 9% to 19,984 units (SEC Form 4)
- Regeneron Announces Investor Conference Presentations
- Pasatru™ (garetosmab-grts) First and Only FDA-approved Treatment Demonstrating Reduction in New Heterotopic Ossification (HO) Lesions and Clinician-Assessed Flare-ups in a Placebo-controlled Trial in Adults with Fibrodysplasia Ossificans Progressiva (FOP)
- Director Guarini Kathryn exercised 400 shares at a strike of $719.37 and sold $320,000 worth of shares (400 units at $800.00) as part of a pre-agreed trading plan (SEC Form 4)